New biomarkers in IgA nephropathy

IF 3.8 3区医学 Q2 IMMUNOLOGY

Clinical immunology Pub Date : 2025-02-27 DOI:10.1016/j.clim.2025.110468

Zhixin Xu , Haoting Zhan , Jingdi Zhang, Zhan Li, Linlin Cheng, Qian Chen, Ye Guo, Yongzhe Li

{"title":"New biomarkers in IgA nephropathy","authors":"Zhixin Xu , Haoting Zhan , Jingdi Zhang, Zhan Li, Linlin Cheng, Qian Chen, Ye Guo, Yongzhe Li","doi":"10.1016/j.clim.2025.110468","DOIUrl":null,"url":null,"abstract":"<div><div>Currently, IgA nephropathy (IgAN) is the most common cause of chronic renal failure in patients with primary glomerulonephritis. However, IgAN diagnosis is usually performed by collecting a renal biopsy as gold standard to visualize pathological changes in the glomeruli. The randomized nature of this invasive procedure in clinical practice, together with the need to exclude patients with contraindications, often results in a limited number of eligible people. Therefore, over the past two decades, researchers have explored new biomarkers for IgAN to meet the urgent clinical need for rapid diagnosis and prognosis, as well as realistic prediction of IgAN progression. In addition to traditional common markers with low specificity to detect renal diseases, the classical antibody targeting galactose-deficient IgA1 has been progressively discovered. In addition, new types of diagnostic or prognostic biomarkers are emerging, including microRNA, complement factors, proteases, inflammatory molecules and serum or urinary metabolite profiles.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"274 ","pages":"Article 110468"},"PeriodicalIF":3.8000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521661625000439","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Currently, IgA nephropathy (IgAN) is the most common cause of chronic renal failure in patients with primary glomerulonephritis. However, IgAN diagnosis is usually performed by collecting a renal biopsy as gold standard to visualize pathological changes in the glomeruli. The randomized nature of this invasive procedure in clinical practice, together with the need to exclude patients with contraindications, often results in a limited number of eligible people. Therefore, over the past two decades, researchers have explored new biomarkers for IgAN to meet the urgent clinical need for rapid diagnosis and prognosis, as well as realistic prediction of IgAN progression. In addition to traditional common markers with low specificity to detect renal diseases, the classical antibody targeting galactose-deficient IgA1 has been progressively discovered. In addition, new types of diagnostic or prognostic biomarkers are emerging, including microRNA, complement factors, proteases, inflammatory molecules and serum or urinary metabolite profiles.

查看原文本刊更多论文

IgA 肾病的新生物标记物

目前，IgA肾病（IgAN）是原发性肾小球肾炎患者慢性肾功能衰竭最常见的原因。然而，IgAN的诊断通常是通过收集肾活检作为金标准来观察肾小球的病理变化。在临床实践中，这种侵入性手术的随机性，加上需要排除有禁忌症的患者，往往导致符合条件的患者数量有限。因此，在过去的二十年中，研究人员一直在探索新的IgAN生物标志物，以满足快速诊断和预后的迫切临床需求，以及对IgAN进展的现实预测。除了检测肾脏疾病的传统低特异性的常见标记物外，针对半乳糖缺乏IgA1的经典抗体已逐渐被发现。此外，新型的诊断或预后生物标志物正在出现，包括microRNA、补体因子、蛋白酶、炎症分子和血清或尿液代谢物谱。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical immunology 医学-免疫学

CiteScore

12.30

自引率

1.20%

发文量

212

审稿时长

34 days

期刊介绍： Clinical Immunology publishes original research delving into the molecular and cellular foundations of immunological diseases. Additionally, the journal includes reviews covering timely subjects in basic immunology, along with case reports and letters to the editor.